AI Terminal
ABIVAX
Regulatory Filings • Mar 13, 2023
1063_rns_2023-03-13_7f0e02b7-df80-431a-800f-ecd560df0c0b.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 13 March 2023 12:00
Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
EQS-News: ABIVAX / Key word(s): Miscellaneous
Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
13.03.2023 / 12:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
COMPANY STATEMENT
Abivax does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution
PARIS, France, March 13, 2023 – 12:00 p.m. (CET) – Abivax SA (the “Company”, Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, is aware that Silicon Valley Bank (“SVB”) was closed on March 10, 2023, by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (“FDIC”) as receiver.
The Company does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution, and it does not have any banking relationship with SVB. The Company has no exposure to any liquidity concern at SVB or any other U.S. financial institution.
*****
About Abivax (www.abivax.com)
Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
| Abivax Communications Regina Jehle [email protected] +33 6 24 50 69 63 |
Investors LifeSci Advisors Ligia Vela-Reid [email protected] +44 7413 825310 |
Press Relations & Investors Europe MC Services AG Anne Hennecke [email protected] +49 211 529 252 22 |
| Public Relations France Actifin Ghislaine Gasparetto [email protected] +33 6 21 10 49 24 |
Public Relations France Primatice Thomas Roborel de Climens [email protected] +33 6 78 12 97 95 |
Public Relations USA Rooney Partners LLC Jeanene Timberlake [email protected] +1 646 770 8858 |
13.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com